

CLINICAL PRIORITIES ADVISORY GROUP XX XX XX 2018

Agenda Item No	
National Programme	Trauma
Clinical Reference Group	Neuroscience
URN	1632

Title
Adult Neuropsychiatry and Neuropsychology Service Specification

Actions Requested	1. Agree the service specification
--------------------------	------------------------------------

Proposition
This is a new service specification. CPAG are requested to approve the service specification for adult Neuropsychiatry and Neuropsychology.

Clinical panel recommendation
Select appropriate option: Not applicable

The committee is asked to receive the following assurance:	
1.	The Head of Clinical Effectiveness confirms the proposal has completed the appropriate sequence of governance steps
2.	The Head of Acute Programmes / Head of Mental Health Programme confirms the proposal is supported by an: Impact Assessment; Stakeholder Engagement Report; Consultation Report; Equality Impact and Assessment Report; Service specification. The relevant National Programme of Care has approved these reports.
3.	The Director of Finance (Specialised Commissioning) confirms that the impact assessment has reasonably estimated a) the incremental cost and b) the budget impact of the proposal.
4.	The Operational Delivery Director (Specialised Commissioning) confirms that the service and operational impacts have been completed.

The following documents are included (others available on request):	
1.	Service specification
2.	Consultation Report
3.	Evidence Summary
4.	Clinical Panel Report (N/A)
5.	Equality Impact and Assessment Report

The Benefits of the Proposition			
<i>No</i>	<i>Metric</i>	<i>Grade of evidence</i>	<i>Summary from evidence review</i>
1.	Survival	Not measured	
2.	Progression free survival	Not measured	
3.	Mobility	Not measured	
4.	Self-care	Not measured	
5.	Usual activities	Not measured	
6.	Pain	Not measured	
7.	Anxiety / Depression	Not measured	
8.	Replacement of more toxic treatment	Not measured	
9.	Dependency on care giver / supporting independence	Not measured	
10.	Safety	Not measured	
11.	Delivery of intervention	Not measured	

Considerations from review by Rare Disease Advisory Group

Pharmaceutical considerations

Considerations from review by National Programme of Care
Select appropriate option: The specification received the support of the Trauma PoC Board on the xxx 2018 There is no financial model for this specification as activity is currently reported via the neurology pathway and until specification is in place it is not possible to identify where the costs sit although the service is already provided in neuroscience centre.

SECTION 2 – IMPACT REPORT (Not included in CPAG Papers, section 2 only)

No	Item	N/Cost £K	Level of uncertainty
1.	Number of patients affected in England	N/A	
2.	Total cost per patient over 5 years	£N/A	The 2017/18 spend for Neurosurgery (inpatients) in England was approximately £381.8m and paid for under national tariffs.
3.	Budget impact year 1	£0	Cost Neutral. The revision/ update to the service specification is not expected to change the current commissioned pathway for neurosurgery.
4.	Budget impact year 2	£0	Cost neutral. As described in Section 2. (Box 3.) above.
5.	Budget impact year 3	£0	Cost neutral. As described in Section 2. (Box 3.) above.
6.	Budget impact year 4	£0	Cost neutral. As described in Section 2. (Box 3.) above.
7.	Budget impact year 5	£0	Cost neutral. As described in Section 2. (Box 3.) above.
8.	Total number of patients treated over 5 years	N/A	
9.	Net cost per patient treated over 5 years	N/A	
10.	Estimated proportion of patients benefitting (%)		
11.	Total cost per patient benefitting over 5 years		
Key additional information			
There is no financial model for this service specification as the revision/ update to the service specification is not expected to change the current commissioned pathway for neurosurgery.			